Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Validation of a high resolution NGS method for detecting spinal muscular atrophy carriers among phase 3 participants in the 1000 Genomes Project

Contributed equally
BMC Medical Genetics201516:100

https://doi.org/10.1186/s12881-015-0246-2

Received: 23 June 2015

Accepted: 22 October 2015

Published: 29 October 2015

Abstract

Background

Spinal muscular atrophy (SMA) is the most common pan-ethnic cause of early childhood death due to mutations in a single gene, SMN1. Most chromosome 5 homologs have a functional gene and dysfunctional copy, SMN2, with a single synonymous base substitution that results in faulty RNA splicing. However, the copy number of SMN1 and SMN2 is highly variable, and one in 60 adults worldwide are SMA carriers. Although population-wide screening is recommended, current SMA carrier tests have not been incorporated into targeted gene panels.

Methods

Here we describe a novel computational protocol for determining SMA carrier status based solely on individual exome data. Our method utilizes a Bayesian hierarchical model to quantify an individual’s carrier probability given only his or her SMN1 and SMN2 reads at six loci of interest.

Results

We find complete concordance with results obtained with the current qPCR-based testing standard in known SMA carriers and affecteds. We applied our protocol to the phase 3 cohort of the 1,000 Genomes Project and found carrier frequencies in multiple populations consistent with the present literature.

Conclusion

Our process is a convenient, robust alternative to qPCR, which can easily be integrated into the analysis of large multi-gene NGS carrier screens.

Keywords

1000 Genomes Project Carrier testing DNA-seq Exome-seq Genetic testing Next-generation sequencing (NGS) SMN1 SMN2 Spinal muscular atrophy (SMA)

Background

Spinal muscular atrophy (SMA) is a common autosomal recessive disorder affecting approximately 1/10,000 live births [1]. The disease results from the degeneration of spinal cord motor neurons, which leads to the progressive weakness and deterioration of skeletal muscle, and eventually paralysis and death [2]. SMA is categorized into four clinical types based on disease manifestations and age of onset [3]. Type I (OMIM: 253300) patients have severe muscle weakness within the first three months of life; death usually occurs within the first two years. Patients with Type II SMA (OMIM: 253550) are able to sit, but cannot stand or walk; they typically survive beyond four years. Type III SMA (OMIM: 253400) is a milder form of SMA; these patients are diagnosed later in their youth and can walk unaided [2, 3]. The mildest adult-onset form of SMA (Type IV, OMIM: 271150) is found in patients who can walk into adulthood [2].

All autosomal recessive forms of SMA disease are caused by variant forms of the SMN locus on chromosome 5 (chr5), which ordinarily contains two nearly identical copies of a gene encoding the survival of motor neuron gene product [4]. The two gene copies, referred to as SMN1 and SMN2, were derived through a recent duplication event along the human lineage (Fig. 1) [5]. They have identical exon-intron organizations and the potential for the same gene product.
Fig. 1

Evolution of the human SMN locus. a. The human SMN1 and SMN2 genes were derived by duplication of a proto-SMN gene after the human-chimpanzee split. The yellow bar represents the only functional base change that distinguishes SMN2 from SMN1 (on chromosome 5 at position 69,372,353 in the GRCh37/hg19 reference genome) which is signified on the canonical transcript position as c.840C > T. The copy number of each gene on a single chromosome is indicated in the bracket and colon formulation [SMN1:SMN2]. A canonical SMN chromosomal locus consists of one copy of each gene in the centromere-telomere order SMN2-SMN1. A canonical homozygous genotype is represented as [1:1]/[1:1]. b. Comparison of SMN1 and SMN2 sequences on either side of the gene-defining c.840C > T base difference. c. Three categories of interlocus homologous recombination between SMN1 and SMN2 generate copy number variants of the SMN locus. 1. Recombination and exchange on the centromeric side of the SMN2-defining base; 2. recombination and exchange on the centromeric side of the SMN2-defining base; 3. interlocus gene conversion across the SMN2-defining base region, indicated with the double-arrowed line. d. Each recombination event produces two variant SMN chromosome types which are cross-referenced from panel c. Variant chromosomes are ordered by total SMN copy number

SMN1 and SMN2 are typically distinguished by a handful of single nucleotide differences, only one of which has an impact on the corresponding polypeptide [2, 59]. This single functional difference occurs at the sixth base of the eighth exon (referred to traditionally as exon 7) (840 C > T). The SMN2 base (T) is synonymous in terms of amino acid coding, but causes a rate of exon-skipping of 50-90 % (depending on the tissue analyzed) and corresponding reduction of gene functionality (Fig. 1b, Additional file 1: Figure S1a) [1013].

Variant forms of the SMN locus are produced at a frequency of approximately 1 in 10,000 by intergenic meiotic recombination between homologous regions within and around SMN1 and SMN2 (Fig. 1c). Unequal crossing-over generates two chromosomal products containing one gene or three genes, respectively. Depending on the location of the cross-over event, the single gene chromosome will carry either SMN1 or SMN2, and the three gene chromosome will have a 1:2 or 2:1 SMN1:SMN2 ratio (Fig. 1d). Alternatively, at a much lower frequency, heteroduplex formation across the gene-defining SMN location will resolve without crossing over, leading to gene conversion. Gene conversion does not alter copy number but can result in two copies of either SMN1 or SMN2. Due to the high degree of repetitive sequence in SMN1, intragenic recombination is also quite likely and can lead to deleterious variations [14].

As a result of recombination in the SMN locus, a large degree of variability in SMN1 and SMN2 copy number exists in the global human population [14]. Up to 15 % of individuals lack SMN2 completely, while others can have three or more copies of this gene [10, 1417]. However, all variant chromosomes formed by intergenic recombination must carry at least one SMN gene that may be SMN1 or SMN2.

Carrier frequency for SMA ranges from about 1/47 in European populations to 1/72 in African Americans [10, 18, 19]. Approximately 95 % of SMA cases are a consequence of SMN1 gene transformation by unequal crossing over or gene conversion [20]. Most of the remaining SMA affected patients are compound heterozygotes with intragenic mutations in their single remaining copy of SMN1 [4, 10, 15].

Prompted by the severity of SMA and its high pan-ethnic incidence rate, the American College of Medical Genetics and Genomics has recommended universal SMA carrier testing in order to identify couples at risk of conceiving an SMA affected child [21]. The conventional SMA screening protocol involves some form of quantitative polymerase chain reaction (qPCR) directly, or in combination with multiplex ligation-dependent probe amplification (MLPA), TaqMan, restriction fragment length polymorphism, denaturing high-performance liquid chromatography, or direct (Sanger) sequencing [15, 2227] (see [28] for a review). qPCR primers are designed specifically to amplify segments of exon 7 containing the SMN1-defining sequence. The copy number of SMN1 is calculated by comparing its cycle threshold directly to that of a control gene(s). One of the most robust methods to detect SMA carriers is MLPA, a qPCR based method that utilizes fragment fluorescence intensity to determine SMN1 and SMN2 copy number [23, 29, 30].

While existing qPCR approaches are accurate on a case-by-case basis, none of the current processes can be incorporated into cost-effective NGS screens for the simultaneous detection of carrier status at hundreds of genes [31]. In this paper we present a novel Bayesian analysis protocol to determine the probability that an individual is an SMA carrier given only his or her sequencing coverage at a few sites of interest. We applied our technique to known SMA carriers and over fifty samples with unknown genotypes. Our NGS method accurately predicted the status of known carriers, and provides output as a continuous likelihood, rather than a binary scale, for each individual. We applied our algorithm to determine the carrier status of individuals from the Phase 3 release of the 1000 Genomes Project [32] to demonstrate its effectiveness in a large diverse sequencing study where qPCR is not a reasonable alternative. Our statistical approach is a useful method for determining SMA carrier status from only DNA-sequencing data and should be part of a large NGS carrier-testing platform.

Methods

Sample collection and initial processing

We collected semen or saliva samples from volunteers. We anonymized sample names to conceal personal identification information.

Saliva samples were collected with the Oragene Dx (ODG-510) collection kit (DNA Genotek, Kanata Ontario, Canada). Genomic DNA was extracted from saliva samples using the prepIT L2P (DNA Genotek, Kanata Ontario, Canada) reagents per the manufacturer’s instructions. Semen samples were immediately cryopreserved at −190 °C after collection. DNA was extracted from the semen samples using the MasterPure Complete DNA & RNA Isolation Kit (Epicenter, Madison WI, USA) according to the manufacturer’s specifications. Genomic DNA from both saliva and semen were re-purified using the Genomic DNA Clean and Concentrator-5 Kit (Zymo Research, Irvine CA, USA) according to the manufacturer’s protocol.

The integrity for both the saliva- and semen-extracted DNA was verified by electrophoresis in 2 % agarose gels. DNA concentration and quality were measured with the Qubit dsDNA HS Assay kit (Life Technologies, Grand Island NY, USA) and the NanoDrop 8000 spectrophotometer (NanoDrop, Wilmington DE, USA). NanoDrop OD ratios above 1.7 for A260/280 and above 1.7 for A260/230 indicate high purity of samples. Final DNA concentration for each sample was adjusted to 4 μg/ml, a sufficient amount to obtain at least 2 μg of genomic DNA per sample. Final DNA samples were aliquoted and stored at −20 °C prior to use. Genomic DNA samples that did not meet OD ratios above 1.7 and had DNA content below 100ng were re-collected or removed from NGS processing.

Additionally, 2,532 aligned BAM files from the Phase 3 of the 1000 Genomes Project (1KG3) were downloaded for subsequent processing (ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/) [32]. We removed 31 samples that were classified as related by the 1000 Genomes Project Consortium.

Ethics, consent and permissions

The GenePeeks Research Ethics Committee approved research use of saliva and semen samples. All samples were previously collected from volunteers consenting to use their sample and derivative information for additional genetic testing or future research. We obtained written consent from all participants.

Consent to publish

Each volunteer participant gave written consent to publish his or her individual data.

Sequencing

The Illumina TruSight Inherited Disease panel (Illumina, San Diego CA, USA) was chosen to sequence samples. The panel contains 552 disease-associated genes, including SMN1 and SMN2. A total of 150 ng of genomic DNA collected from saliva, semen, and Coriell Institute DNA samples were prepared with the panel according to the manufacturer’s protocol. Pooled libraries were size selected on the Pippin Prep (Sage Sciences, Beverly MA, USA) for 300-700bp and were sequenced on the Illumina MiSeq at 2x 300 cycles.

Bioinformatics processing

We used the Burrows-Wheeler Alignment tool (BWA MEM) [33] to align the sequence reads to the human reference genome, GRCh37/hg19 (downloaded from the Genome Analysis Toolkit (GATK) version 2.8), creating a single aligned BAM file for each individual saliva, sperm, and Coriell sample. Potential PCR duplicate reads were marked by running the aligned subject data through the Picard MarkDuplicates tool (http://broadinstitute.github.io/picard/). We then performed local realignment for each sample by using the GATK IndelRealigner tool followed by recalibrating base qualities using the GATK BaseRecalibration tool, both according to GATK recommended best practices [34].

The average gene coverage for individual genes was determined for each saliva, sperm, Coriell, and 1KG3 sample by running the resulting BAM files through GATK’s DepthOfCoverage analysis tool. Total coverage for three SMN1 loci on chromosome 5 (chr5:70,247,724, chr5:70,247,773, and chr5:70,247,921) and three SMN2 loci (chr5:69,372,304, chr5:69,372,353, and chr5:69,372,501) was parsed from the output data from the DepthOfCoverage tool.

MLPA

Copy number status was determined by Multiplex ligation-dependent probe amplification (MLPA) [23]. We used 200ng per sample reaction of genomic DNA from human saliva, semen, and Coriell Institute DNA samples with the SALSA MLPA SMA P060 probe mix kit (MRC-Holland, Netherlands) according to the manufacturer’s protocol (Additional file 2: Table S1). The MLPA PCR products were separated and captured for probe fluorescence intensity by capillary electrophoresis on the ABI3730XL (Applied Biosystems, Foster City CA, USA). Raw data files were analyzed for copy number status on the Coffaylser. NET software (MRC-Holland, Netherlands). Two Coriell Institute samples with 1 copy of SMN1 and 2 copies of SMN2 were chosen as positive controls for MLPA. We chose three reference controls that have 2 copies of SMN1 and 2 copies of SMN2 from a previous MLPA experiment using SD019 Reference DNA (MRC-Holland, Netherlands) as the SMA normal reference control. Samples were run in duplicate; final SMN1 to reference ratios reported in the main text and tables represent averages of these values.

SMN1 reads at loci of interest

We consider N subjects. Let D bi = 0, 1, 2, …,r bi be the number of reads that align to SMN1 in the ith subject (i = 1,2,…,N) at chr5:70,247,773, where r bi is the total number of reads aligned to the SMN1 region (chr5:70,247,773) and the analogous SMN2 region (chr5:69,372,353). Note that these two loci, denoted with the letter ‘b’ and located in exon 7 of their respective genes, correspond to the only coding differences between SMN1 and SMN2. We also examined two intronic loci on either side of exon 7 symbolized by a (chr5:70,247,724 in SMN1 and chr5:69,372,304 in SMN2) and c (chr5:70,247,921 in SMN1 and chr5:69,372,501 in SMN2).

We use πi to represent the probability that a SMN1 or SMN2 (denoted as SMN) read is actually from SMN1 in the ith subject. We define \( {\widehat{\pi}}_{bi} \) as the observed proportion of SMN reads that align to SMN1 in exon 7 (i.e., \( {\widehat{\pi}}_{bi}={D}_{bi}/{r}_{bi} \)), and calculated \( {\widehat{\pi}}_{ai} \) and \( {\widehat{\pi}}_{ci} \) in a parallel manner. Our observed proportion of SMN1 reads is \( {\widehat{\pi}}_i={D}_i/{r}_i \) , where, for most samples, D i is the total number of SMN1 reads and r i is the total number of SMN reads at our three loci of interest (i.e., D i  = D ai  + D bi  + D ci and r i  = r ai  + r bi  + r ci ). If \( \left|{\widehat{\pi}}_{bi}-{\widehat{\pi}}_{ai}\right|>\in \) or \( \left|{\widehat{\pi}}_{bi}-{\widehat{\pi}}_{ci}\right|>\in \), for some  > 0 ( = 0.10, here), then the so-called condition is not met and we let D i= D bi and r i= r bi .

Scaled SMN1 reads

To further account for SMN1 copy number, we considered K “housekeeping” or control genes (k = 1, 2,…, K) and calculate z ki = (c 1i + c 2i )/H ki , where c 1i is the average coverage for the SMN1 gene region, c 2i is the average coverage for SMN2, and H ki is the average coverage for gene k in the ith subject.

For each person, we calculated a weighted average of the coverage of SMN1 to our K housekeeping genes: \( {\widehat{\theta}}_i=\frac{{\displaystyle {\sum}_{k=1}^K{z}_{ki}/{\overline{z}}_k}}{K} \), where \( {\overline{z}}_k=\frac{{\displaystyle {\sum}_{i=1}^N{z}_{ki}}}{N} \) and N is the total number of subjects. For conservatism, any values of \( {\widehat{\theta}}_i>1.0 \) are set to 1.0 so that our scaling factor has a ceiling of 1.00 (i.e., \( {\widehat{\theta}}_i\in \left[0,1\right] \)).

Selecting housekeeping genes representative of genome-wide copy-number is nontrivial. We wanted to only include genes that have sufficiently high coverage in the majority of subjects. Genes with low coverage (lower than the 5th percentile in at least 10 % of subjects) were not considered. Those that passed this coverage filter were then selected for one of two properties: (1) low variability in average coverage across all samples or (2) low variability in z ki across all samples. To account for differences in scale, we used the coefficient of variation across all samples (\( \widehat{\theta}/\widehat{\mu} \)) to rank the variability of each gene. We chose the top ten genes according to properties (1) and (2) for a total of K = 20 control genes. Unlike other copy number determining algorithms, our housekeeping genes do not necessarily need to be 2-copy across all samples, but they do need consistent coverage relative to SMN.

We use \( {\widehat{\theta}}_i \) to scale our observed SMN1 reads to \( {D_i}^{\prime }={\widehat{\theta}}_i{D}_i \) and let \( {{\widehat{\pi}}_i}^{\prime }={D_i}^{\prime }/{r}_i \) represent our scaled estimate of π i . In this way, we account for the number of SMN reads relative to low variability regions.

Bayesian hierarchical model

Assuming that we align to either a SMN1 or SMN2 at our polymorphic sites, the (scaled) number of SMN1 reads is binomially distributed: \( {D_i}^{\prime }=\widehat{\theta}{D}_i\sim Bin\left({r}_i,{\pi}_i\right) \), where πi is the probability that a SMN read is actually from SMN1 in the ith subject. Thus, \( P\left({D_i}^{\prime }={d}_i\left|{r}_i,{\pi}_i\right.\right)=\left(\begin{array}{c}\hfill {r}_i\hfill \\ {}\hfill {d}_i\hfill \end{array}\right){\pi}_i^{d_i}{\left(1-{\pi}_i\right)}^{r_i-{d}_i} \). The binomial distribution allows us to model the reads in our dataset; however, we are more interested in making inference about π i . In particular, we want to know
$$ \begin{array}{c}\mathrm{P}\left(\mathrm{subject}\ \mathrm{is}\ \mathrm{a}\ \mathrm{c}\mathrm{a}\mathrm{rrier}\Big|\mathrm{sequencing}\ \mathrm{data}\right) = \mathrm{P}\left(\mathrm{ratio}\ \mathrm{o}\mathrm{f}\kern0.5em SMN 1\kern0.5em \mathrm{reads}\ \mathrm{t}\mathrm{o}\kern0.5em SMN 2\kern0.5em \mathrm{reads}\ \mathrm{is}\ 1:2,\ 1:3,\ \mathrm{e}\mathrm{t}\mathrm{c}.\right)\\ {} = \mathrm{P}\left(\mathrm{proportion}\ \mathrm{o}\mathrm{f}\ SMN 1\kern0.5em \mathrm{reads}\ \mathrm{is}\ 1/3,\ 1/4,\ \mathrm{e}\mathrm{t}\mathrm{c}.\right)\\ {} = P\left({\pi}_i\le\ 1/3\Big|{D}_i^{\prime },\ {r}_i\right).\end{array} $$
To this end, we use a Bayesian hierarchical model and assume a (conjugate) prior for π i : π i  Beta(α, β). Thus, the posterior distribution for π i is also a beta distribution:
$$ {\pi}_i\left|{D_i}^{\prime },{r}_i\right.\sim Beta\left(\alpha +{D_i}^{\prime },{r}_i-{D_i}^{\prime }+\beta \right),\forall i. $$
We calculate P(π i  ≤ 1/3|D i ′, r i ) directly via the cumulative distribution function of our posterior beta distribution. In order to conservatively capture all potential carriers, we allow a 5 % “Type I error” and present carrier probability results calculated As P(π i  ≤ 0.38|D i ′, r i ) rather than P(π i  ≤ 1/3|D i ′, r i ). We considered both a uniform prior (α = β = 1) and Jeffreys noninformative prior (α = β =1/2).

This method can easily be extended to the case where our loci are not biallelic with a multinomial-Dirichlet Bayesian hierarchical model.

Sample categorization

We classified each sample into one of three categories based on its corresponding credible interval. Individuals with 95 % credible intervals for π entirely below 0.38 are “likely” carriers; those with intervals that span 0.38 are “possibly” carriers. All others are “unlikely” carriers. Our posterior carrier probability (and corresponding credible intervals) is calculated to determine the probability that an individual has a true π ≤ 0.38 given the data. Unlike frequentist confidence intervals, there is a 95 % chance that the true π is in the bounds of the given 95 % credible interval. Thus, if an individual’s credible interval contains 0.38, it is literally possible that he or she is an SMA carrier. Note that because our final posterior carrier probability is continuous on the [0,1] scale, this metric is more meaningful than the discrete “likely”, “possible”, and “unlikely” carrier categorizations. We recommend that clinical users of our method verify results by MLPA for “possible” carriers in the clinic.

Theoretical results

In theory, the copy number ratio of SMN1, SMN2, and each housekeeping region are consistent among all individuals with two copies of SMN1, SMN2. Thus, normal SMA copy number individuals will have a \( {z}_{ki}/{\overline{z}}_k=1 \) and a calculated weighted average \( {\widehat{\theta}}_i=1 \) (Additional file 3: Table S2). Those with fewer than two copies of SMN1 and/or SMN2 will have \( {\widehat{\theta}}_i<1 \) (Additional file 3: Table S2). Observed carrier frequencies were taken from [14] and [16].

To determine the relationship between coverage and carrier probability, we obtained 1,000 random realizations of D|r,π and calculated the average P(π ≤ 0.38|D, r) for a given value of r and π.

Results

Volunteer, Coriell, and 1000 Genomes Samples sequenced for carrier testing

To determine the accuracy of our method, we collected and sequenced DNA from 56 healthy volunteers and 15 samples from the Coriell Institute. The volunteer samples were collected via saliva (nsaliva = 47) or semen (nsemen = 7); there was no difference in their average sequencing coverage (p-value = 0.195). The Coriell cohort included nine positive controls: five individuals affected with SMA and four SMA carriers. We also analyzed six diagnosed non-SMA diseased control Coriell samples: two normal healthy controls (NHC), two with amyotrophic lateral sclerosis (ALS), one with Duchenne muscular dystrophy (DMD), and one with X-linked SMA (SMAX1). While four of these individuals are affected with a neuromuscular disease having a notable genetic component, they are only as likely as a randomly selected individual to be an SMA carrier. Additionally, we processed the raw sequencing data from 2,501 unrelated members of the 1000 Genomes Project Phase 3 (1KG3) release; the carrier status of these samples was completely unknown.

Novel sequencing-based SMA carrier detection method

We developed a Bayesian hierarchical model to quantify the probability that an individual has at most one copy of SMN1 given his or her distribution of aligned DNA-seq reads to SMN1 at three nucleotide differences that distinguish canonical SMN1 and SMN2 (Methods, Additional file 1: Figure S1b). Briefly, we assume that the number of reads aligning to the loci in SMN1 and SMN2 can be modeled by a binomial distribution with a fixed number of total reads and probability, π, that a read aligned to this region is actually from SMN1. We found almost no difference between the outcomes of two uninformative priors for our model (Additional file 4: Figure S2) and proceeded with Jeffreys conjugate prior.

Given our sequencing data and prior, the posterior of our parameter of interest (π) follows a closed-form beta distribution, making corresponding carrier probabilities computationally easy to calculate (Methods). The chance of being a carrier is inversely proportional to the number of reads aligned to SMN1; subjects with an observed estimate of π (denoted as \( \widehat{\pi} \)) less than 1/3 have high carrier probabilities (Additional file 3: Table S2).

We simulated 1,000 individuals at three carrier and five non-carrier SMN1:SMN2 copy number ratios (0, 1:3, & 1:2, and 2:3, 1:1, 2:1, 3:1, & 1:0, respectively) with various SMN total reads (1 to 3,000) and calculated their average carrier probabilities with our method (Methods). For hypothetical carriers (π ≤ 1/3), a minimum of 350 SMN reads are needed to obtain an average carrier probability of 0.90 (i.e., 90 % sensitivity; Fig. 2). However, even with 150 SMN reads, the average posterior probability among simulated carriers is at least 0.80 (Fig. 2b). With just 10 reads aligning to our loci of interest in SMN, SMA affected individuals (i.e., SMN1:SMN2 = 0, π = 0) can be assigned an average probability of at least 0.998 for having one or fewer SMN1 gene copies. Non-carriers with at least a 1:1 SMN1:SMN2 ratio (π ≥ ½) have an average carrier probability less than 0.10 (90 % sensitivity) with more than 75 reads, and 0.001 (99.9 % sensitivity) with more than 200 reads. Simulated individuals without any SMN2 copies have an average carrier probability less than 10−5 with just 10 reads. Non-carrier subjects with a 2:3 SMN1:SMN2 ratio (π = 2/5), require at least 1,000 reads for a carrier probability less than 0.20 (Fig. 2a).
Fig. 2

Simulation results of the number of SMN reads versus the posterior carrier probability for various levels of π for a maximum of (a) 3,000 and (b) 350 reads. Each point represents the average across 1,000 permutations. The red, blue, and green lines correspond to values of π less than or equal to 1/3 correspond to true carriers

For most subjects (95.8 % in the volunteer and Coriell cohort and 74.3 % in 1KG3 set), we pooled data obtained from all three canonical SMN1-defining base positions. However, if the proportion of reads that aligned to SMN1 at either of our two intronic sites differed from the one in exon 7 by more than 10 %, we calculated our observed proportion based only on the reads aligning to the unique site in exon 7. The three volunteer and 642 1KG3 subjects for whom this is the case have significantly lower coverage in this region of the genome compared to those samples that do not fail the 10 % criterion (p-values = 5.46 x 10−6 and 3.45 x 10−8, respectively).

Scaled SMN1 reads

Because the DNA sequences of SMN1 and SMN2 are so similar, and their copy numbers so variable, we extended our method to compare the total SMN coverage in each sample to that of several “housekeeping” genes. These genes were selected based on their high coverage and low variability in the majority of subjects (Methods). Individuals with a canonical genotype (Fig. 1a) will have one read aligning to SMN1 and SMN2 (4 total copies) for every reference gene (2 copies). We account for the number of SMN copies with a weighted average of the SMN to housekeeping genes ratio (our “scaling factor”), which is capped at 1.00. We multiply the number of reads aligning to our loci of interest in SMN1 by this scaling factor, and use these values to estimate the scaled probability that a read aligned to this region is actually from SMN1 (denoted as \( {\widehat{\pi}}^{\prime } \)).

We examined 20 distinct housekeeping genes in the volunteer, Coriell (Additional file 5: Table S3) and 1KG3 samples (Additional file 6: Table S4). Only three genes (FASTKD2, RAB3GAP1, and SLC35D1) were included on both lists.

The estimate of π for the majority of samples was not drastically affected by the scaling of reads (Additional file 7: Table S5, Additional file 8: Table S6, Additional file 9: Figure S3). About half of the volunteer and Coriell samples (54.9 %) and of 1KG3 samples (52.1 %) have scaling factors not equal to 1.0, with average values of 0.84 (Additional file 7: Table S5, Additional file 8: Table S6). The saliva and semen volunteer samples do not have different average scaling factors (p-value = 0.137). The estimates of π before and after scaling are very tightly correlated for both cohorts (Spearman rank correlation ≥ 0.96, p-values < 2.2 x 10−16). Further, only three volunteer and Coriell samples (A23, C15, and NA03185) and 30 1KG3 samples had carrier probabilities that differed by more than 0.1 due to scaling (Additional file 7: Table S5, Additional file 8: Table S6).

Sequencing method accurately classifies SMA carriers and non-carriers

The distribution of \( {\widehat{\pi}}^{\prime } \) is multimodal among the healthy volunteer and Coriell subjects, with the highest peak near 0.5, corresponding to an equal copy number for SMN1 and SMN2 (Additional file 10: Figure S4a). There is no difference in the average \( {\widehat{\pi}}^{\prime } \) values for the saliva versus sperm samples (p-value = 0.507). The six subjects with values of \( {\widehat{\pi}}^{\prime } \) at or near 1.0 have a homozygous loss of SMN2, and the five with \( {\widehat{\pi}}^{\prime } \) values at or near 0.0 have a homozygous loss of SMN1 (i.e., they are affected with SMA).

As expected, the relationship between \( {\widehat{\pi}}^{\prime } \) and the posterior probability that π is less than 0.38 given the data (i.e., the carrier probability) has a reverse sigmoidal shape (Fig. 3a). Subjects with low values for \( {\widehat{\pi}}^{\prime } \) have very high carrier probabilities, and vise-versa. Individuals with 95 % credible intervals for π that include 0.38 are “possible” carriers, with intermediate posterior probabilities (Fig. 3b). Subjects with high coverage at our SMN gene-defining base positions have very narrow credible intervals (Additional file 7: Table S5).
Fig. 3

Results for volunteer and Coriell samples. a. Estimate of the scaled proportion of SMN reads that are from SMN1 versus the carrier probability for each subject. The carrier probability can be interpreted as the probability that a point on the x-axis falls to the left of the vertical line at 0.38. Samples where few SMN reads align to SMN1 are likely SMA carriers, whereas those with a high proportion of SMN1 reads are unlikely SMA carriers. b. 95 % Posterior (credible) intervals for π are plotted for each subject. In both (a) and (b), subjects that did not meet our 10 % threshold across our three loci are labeled with stars. Note that their intervals in (b) are much wider due to their low coverage. Subjects in both plots are colored red if their credible interval is entirely below the 0.38 cutoff (vertical blue line) and orange if their interval overlaps with 0.38

One Coriell subject (NA03815), who fathered two affected offspring, had an SMN1 to SMN2 reads ratio close to \( 1:1\left(\widehat{\pi}=0.53\right) \). Without scaling, he has a very low carrier probability (2.14 x 10−92). However, after scaling, the proportion of his SMN reads attributable to SMN1 is 0.26, resulting in a final carrier probability of 1.0 (Additional file 7: Table S5). A volunteer’s saliva sample (A23) had a similar pattern (initial carrier probability of 9.00 x 10−10, final carrier probability of 0.83). The most parsimonious explanation for these two cases is that both individuals have a single SMN gene with two recombination-derived alleles (represented as r1 and r3 in Fig. 1d). Thus, in formal genetic terms, these two individuals are heterozygous for a single base mutation in SMN1 (i.e., SMN2).

In addition to NA03815, all of the known SMA carriers and affecteds have a carrier probability of 1.0 according to our computational protocol (Additional file 7: Table S5). The five affected SMA samples have \( {\widehat{\pi}}^{\prime } \) values near 0.0, and 95 % credible intervals for π with upper bounds below 0.02 (Additional file 7: Table S5, Fig. 3b). The four unaffected SMA carriers have 95 % credible intervals for π with upper bounds below 0.33. One of our non-SMA diseased control Coriell samples (NA11067), is a male with SMAX1 (OMIM: 313200), an X-linked version of SMA caused by an expansion in AR (see [35] for a review); he also has an SMA carrier probability of \( 1.0\left({\widehat{\pi}}^{\prime }=0.32\right) \). The maximum carrier probability of the five other non-SMA diseased control Coriell samples (who were NHCs or affected with DMD or ALS) is 3.35 X 10−6 (Additional file 7: Table S5).

Among the volunteer samples, one (C21) is a clear carrier (\( {\widehat{\pi}}^{\prime } \) = 0.30, carrier probability = 1.0). Three others (A23, C15, and M21) are possible SMA carriers, with posterior probabilities above 0.10 (Additional file 7: Table S5).

Sequencing carrier status replicated by MLPA

We used MLPA to determine the carrier status for a subset of our volunteer and Coriell samples. Of the 24 volunteer samples that were not chosen for MLPA, eight had insufficient DNA quantities (≤495ng of DNA, a minimum of 600ng was needed for MLPA) after using these samples for DNA-seq. We are confident that an additional 16 individuals have at least two copies of SMN1 due to their high coverage (average SMN reads = 1352.13, range = [372, 2764]) and values for \( {\widehat{\pi}}^{\prime } \) (average \( {\widehat{\pi}}^{\prime } \) = 0.539, range = [0.460, 0.680]) which led to their exclusion from the MLPA analysis. None of these samples were likely carriers (carrier probability ≤ 2.86 X10−8; Additional file 7: Table S5).

We found a strong correlation between the sequencing-based and MLPA carrier statuses for each sample (Fig. 4, Additional file 7: Table S5). Eleven of the twelve samples that are carriers by the MLPA method (SMN1:reference < 0.7) have a carrier probability of 1.0, and the twelfth sample (A23) has a very high carrier probability (0.83) based on our sequencing method (Additional file 7: Table S5; Fig. 4). Further, only two of the 35 non-carriers (MLPA SMN1:reference > 0.7) have carrier probabilities above 7.51 X 10−6 based on their sequencing data; these two have low posterior probabilities of 0.25 (C15) and 0.11 (M21) (Additional file 7: Table S5; Fig. 4). The SMAX1 Coriell subject (NA11067) is a carrier based on his MLPA result (SMN1:reference = 0.52).
Fig. 4

Results from the MLPA analysis in 60 subjects. a. Carrier probability for each sample stratified by MLPA category. b. Ratio of SMN1 exon 7 to reference sample versus carrier probability for each sample. Vertical lines at 0.7 and 1.3 represent thresholds for copy number loss and gain, respectively. In both (a) and (b), tan, black, and green points represent samples that have less than, equal, and more than two copies of SMN1 exon 7, respectively

Proportion of 1KG3 carriers closely matches corresponding population

Consistent with the published frequencies for SMN1 and SMN2 copy numbers [15, 17] and the results for the volunteer and Coriell subjects, the multimodal distribution of the ratio of SMN1 to SMN reads has peaks near the three most common genotypes: 0.50 (corresponding to a 2:2 SMN1:SMN2 ratio), 0.67 (2:1 SMN1:SMN2 ratio), and 1.0 (2:0, 3:0, or 4:0 SMN1:SMN2 ratio) (Additional file 10: Figure S4b).

Based on our ternary groupings, there are 16 1KG3 subjects who are high-probability carriers, 109 possible carriers, and 2,376 unlikely carriers (Fig. 5, Additional file 8: Table S6, Additional file 11: Figure S5). The possible carriers had significantly lower coverage than the other 2,392 individuals in this cohort (average total coverage of 248.0 and 486.9, respectively, p-value = 9.59 X 10 −15).
Fig. 5

Results for 1000 Genomes samples. a. Estimate of the scaled proportion of SMN reads that are from SMN1 versus the carrier probability for each subject. b. 95 % Posterior (credible) intervals for π are plotted for subjects with the lowest 200 estimates of π. In both (a) and (b), subjects are colored and labeled under the same criteria as in Fig. 3

In order to compare the carrier frequency in five 1KG3 superpopulations to those from a recent large meta-analysis [14], we reclassified all subjects into binary “carrier” and “non-carrier” divisions. We assigned all subjects who are more likely than not to be carriers as “carriers” (posterior probability >0.5), and all others as “non-carriers”. Even though some of these subjects have lower than optimal coverage, their posterior probabilities take into account this low coverage and corresponding uncertainty are thus still interpretable.

We found no statistical difference (two-sided exact binomial test, p-value ≥ 0.10) for any population, with the exception of the “Asian Indian” population (p-value = 0.02) (Table 1). However, the Asian Indian frequency was determined from a single study of just 976 individuals [19], where American subjects self-categorized into one of six ethnic groups. Thus, this Asian Indian carrier frequency truly represents self-identified Americans of Indian descent, not a random sample of individuals from the Indian subcontinent. Each of our exact confidence intervals for the carrier frequencies, including the Asian Indian subjects, overlapped with the published intervals.
Table 1

Carrier frequencies for select super-populations in the 1000 Genomes dataset

Superpopulation (subpopulations)

Number of Samples

Number of Carriers (P(carrier) > 1/2)

Carrier frequency, pObs (95 % exact CI)

Published carrier frequency, p0 (95 % CI)

P-value

(H0: pObs = p0)

Caucasian (CEU, FIN, GBR, IBS, TSI)

503

13

0.026 (0.014 , 0.044)

0.022 (0.020, 0.024)

0.543

Black (ACB, ASW, ESN, GWD, LWK, MSL, YRI)

661

4

0.006 (0.002, 0.015)

0.014 (0.009, 0.018)

0.095

Asian (CDX, CHB, CHS, JPT, KHV)

502

6

0.012 (0.004, 0.026)

0.020 (0.016, 0.024)

0.261

Hispanic (MXL, PUR, CLM)

261

6

0.023 (0.009, 0.049)

0.012 (0.006, 0.017)

0.140

Asian Indian (GIH, ITU, STU, BEB, PJL)

489

3

0.006 (0.001, 0.018)

0.020 (0.010, 0.029)

0.022

All

2501

36

0.01 (0.010, 0.020)

0.019 (0.018, 0.020)

0.138

Discussion

We developed and validated a computational protocol to perform SMA carrier screening on individual exome sequence data. Our protocol eliminates the need to test for SMA in a process distinct from all other carrier tests that can be multiplexed in a single targeted gene panel. Previous sequencing methods were restricted by their inability to differentiate between the SMN1 and SMN2 gene paralogs [15]. We overcome this limitation by focusing on three nucleotide positions that are unique to each gene.

We apply a Bayesian model to compute the probability that a given individual is an SMA carrier given his or her sequencing data at these loci. For each subject, we measure his or her actual carrier probability on a continuous scale. In this way, we have a precise quantification of carrier risk, which can lead to a more specific prediction of affected progeny for any given couple.

We tested our technique on healthy volunteers and samples with known carrier status from the Coriell repository. Our sequencing and qPCR based results for these samples led to identical conclusions; all likely carriers (or non-carriers) by one method were carriers (or not) by the other. We analyzed two carriers who have a 1:1 ratio of SMN1 to SMN2 reads. These individuals have one copy each of SMN1 and SMN2, yet their SMN1:SMN2 reads ratio is no different than if they had two copies each of SMN1 and SMN2 (or three, four, etc.) and were not carriers. Nevertheless, we calculated a high carrier probability for both of these subjects because our method scales SMN1 reads relative to several “housekeeping” genes.

We also identified a carrier among our non-SMA diseased control samples. This subject has been diagnosed with SMAX1, and is not listed as an SMA carrier in the Coriell database. However, according to both our method and the MLPA analysis, he is an SMA carrier. This is a crucial characteristic and should be added to his public profile. Because he is an SMA carrier, there is some chance that his SMAX1 affected family members have been misdiagnosed and may actually have SMA.

To demonstrate the utility of our method, we determined the carrier status of 2,501 subjects from the Phase 3 release of the 1000 Genomes Project based on only their available sequencing data. These individuals represent a diverse global sample of adults without severe pediatric disease, and their SMA carrier status was previously unknown. The majority of these samples are not readily available for a wet lab carrier detection method; a DNA-seq method is the only way to determine their SMA carrier status. Our method is able to assign all subjects in this cohort a carrier probability from sequencing data alone, regardless of coverage. This is one of the advantages of our method and a continuous carrier probability outcome. The sequencing-based carrier rates in the 1KG3 data were no different from the consolidation of several PCR-based experiments.

The coverage of SMN necessary to accurately determine carrier status is dependent upon the underlying genotype of a given individual. For use of our method in the clinic, we recommend a at least 350 SMN reads for 90 % sensitivity, with the caveat that 2:3 SMN1:SMN2 subjects may still have intermediate carrier probabilities at this coverage. These individuals are relatively rare (1-3 % of the general population) [16, 17], and have an average carrier probability of only 0.295 at our recommended coverage level based on our simulation.

Because our carrier probabilities and corresponding credible intervals for π incorporate the uncertainty associated with low coverage, samples with fewer than 350 SMN reads can still be analyzed by our method. These low coverage samples will have carrier probabilities closer to ½ (i.e., more uncertainty) and wider intervals than if they had more reads, but for many genotypes, this will not result in the reclassification of a sample. In our analysis, four (5.6 %) of the volunteer and Coriell samples and 1,085 (43.4 %) of the 1KG3 samples (including 91 of 109 of the “possible” carriers) did not meet the recommended coverage. For the purpose of quantifying the carrier status of all subjects given only the provided data at hand, we included everyone in our analysis, regardless of coverage.

As with existing SMA carrier detection methods, our approach cannot take into account haplotype phase nor identify cis, or silent “2 + 0”, carriers (i.e., individuals with at least two copies of SMN1 on one chr5, but no SMN1 the other), without additional information [21]. About 2-5 % of SMA carriers and about 1/800 individuals have the 2 + 0 genotype [3638]. Our method could be extended to utilize distinct population polymorphisms to detect these carriers (e.g., in Ashkenazi Jews [39]). Further, neither our method nor existing methods can be used to prevent progeny with de novo mutations, which occur in approximately 2 % of SMA cases [10, 40].

Conclusions

DNA sequencing has become the preferred tool for recognizing disease-causing variants throughout the genome. Large, multi-gene targeted sequencing panels are the future of clinical carrier testing [41], and there is a critical need for a comprehensive NGS test that includes SMA carrier detection. The protocol presented here should be implemented as part of broad genetic sequencing screening tests to concurrently assess carrier risk for multiple Mendelian diseases with only NGS data. Without the extra step of qPCR, our approach is the sole process that exclusively utilizes DNA-seq output to measure the likelihood of an SMA carrier.

Availability of supporting data

Read counts at the loci of interest in SMN1 and SMN2 for all volunteer samples can be found in Additional file 7: Table S5.

Notes

Abbreviations

1KG3: 

1000 Genomes Project Phase 3

ALS: 

amyotrophic lateral sclerosis

DMD: 

Duchenne muscular dystrophy

MLPA: 

multiplex ligation-dependent probe amplification

NHC: 

normal healthy control

qPCR: 

quantitative polymerase chain reaction

SMA: 

spinal muscular atrophy

SMAX1: 

X-linked SMA

Declarations

Acknowledgements

We are grateful to Maxwell Silver and Regine Lim for insightful comments regarding the development of this method and manuscript. Thank you to Sami Amr and the Translational Genomics group at Partners Healthcare for support and use of their laboratory space. The authors would also like to thank the scientists who produced the data and bioinformatics tools of the 1000 Genomes Project and all of the individual participants who contributed their genomes to this analysis.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
GenePeeks, Inc.
(2)
GenePeeks, Inc.
(3)
Department of Molecular Biology and the Woodrow Wilson School of Public and International Affairs, Princeton University

References

  1. Pearn J. Classification of spinal muscular atrophies. Lancet. 1980;1:919–22.View ArticlePubMedGoogle Scholar
  2. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371:2120–33.View ArticlePubMedGoogle Scholar
  3. Munsat TL, Davies KE. International SMA consortium meeting. (26–28 June 1992, Bonn, Germany). Neuromuscul Disord. 1992;2:423–8.View ArticlePubMedGoogle Scholar
  4. D'Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71.PubMed CentralView ArticlePubMedGoogle Scholar
  5. Rochette CF, Gilbert N, Simard LR. SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens. Hum Genet. 2001;108:255–66.View ArticlePubMedGoogle Scholar
  6. Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155–65.View ArticlePubMedGoogle Scholar
  7. Bürglen L, Lefebvre S, Clermont O, Burlet P, Viollet L, Cruaud C, et al. Structure and organization of the human survival motor neurone (SMN) gene. Genomics. 1996;32:479–82.View ArticlePubMedGoogle Scholar
  8. Melki J, Lefebvre S, Bürglen L, Burlet P, Clermont O, Millasseau P, et al. De novo and inherited deletions of the 5q13 region in spinal muscular atrophies. Science. 1994;264:1474–7.View ArticlePubMedGoogle Scholar
  9. Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AH, et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet. 1999;8:1177–83.View ArticlePubMedGoogle Scholar
  10. Prior TW, Snyder PJ, Rink BD, Pearl DK, Pyatt RE, Mihal DC, et al. Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A. 2010;152A:1608–16.View ArticlePubMedGoogle Scholar
  11. Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. 1997;16:265–9.View ArticlePubMedGoogle Scholar
  12. Martínez-Hernández R, Bernal S, Also-Rallo E, Alías L, Barceló MJ, Hereu M, et al. Synaptic defects in type I spinal muscular atrophy in human development. J Pathol. 2013;229:49–61.View ArticlePubMedGoogle Scholar
  13. Soler-Botija C, Cuscó I, Caselles L, López E, Baiget M, Tizzano EF. Implication of fetal SMN2 expression in type I SMA pathogenesis: protection or pathological gain of function? J Neuropathol Exp Neurol. 2005;64:215–23.PubMedGoogle Scholar
  14. MacDonald WK, Hamilton D, Kuhle S. SMA carrier testing: a meta-analysis of differences in test performance by ethnic group. Prenat Diagn. 2014;34:1219–26.View ArticlePubMedGoogle Scholar
  15. Prior TW, Nagan N, Sugarman EA, Batish SD, Braastad C. Technical standards and guidelines for spinal muscular atrophy testing. Genet Med. 2011;13:686–94.View ArticlePubMedGoogle Scholar
  16. Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet. 2004;12:1015–23.View ArticlePubMedGoogle Scholar
  17. Ogino S, Gao S, Leonard DGB, Paessler M, Wilson RB. Inverse correlation between SMN1 and SMN2 copy numbers: evidence for gene conversion from SMN2 to SMN1. Eur J Hum Genet. 2003;11:275–7.View ArticlePubMedGoogle Scholar
  18. Ogino S, Leonard DGB, Rennert H, Ewens WJ, Wilson RB. Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet. 2002;110:301–7.View ArticlePubMedGoogle Scholar
  19. Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet. 2012;20:27–32.PubMed CentralView ArticlePubMedGoogle Scholar
  20. Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat. 2000;15:228–37.View ArticlePubMedGoogle Scholar
  21. Prior TW. Carrier screening for spinal muscular atrophy. Genet Med. 2008;10:840–2.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70:358–68.PubMed CentralView ArticlePubMedGoogle Scholar
  23. Huang C-H, Chang Y-Y, Chen C-H, Kuo Y-S, Hwu W-L, Gerdes T, et al. Copy number analysis of survival motor neuron genes by multiplex ligation-dependent probe amplification. Genet Med. 2007;9:241–8.View ArticlePubMedGoogle Scholar
  24. Anhuf D, Eggermann T, Rudnik-Schöneborn S, Zerres K. Determination of SMN1 and SMN2 copy number using TaqMan technology. Hum Mutat. 2003;22:74–8.View ArticlePubMedGoogle Scholar
  25. van der Steege G, Grootscholten PM, van der Vlies P, Draaijers TG, Osinga J, Cobben JM, et al. PCR-based DNA test to confirm clinical diagnosis of autosomal recessive spinal muscular atrophy. Lancet. 1995;345:985–6.View ArticlePubMedGoogle Scholar
  26. Sutomo R, Akutsu T, Takeshima Y, Nishio H, Sadewa AH, Harada Y, et al. Rapid SMN1 deletion test using DHPLC to screen patients with spinal muscular atrophy. Am J Med Genet. 2002;113:225–6.View ArticlePubMedGoogle Scholar
  27. Kubo Y, Nishio H, Saito K. A new method for SMN1 and hybrid SMN gene analysis in spinal muscular atrophy using long-range PCR followed by sequencing. J Hum Genet. 2015;60:233–9.View ArticlePubMedGoogle Scholar
  28. Nurputra DK, Lai PS, Harahap NIF, Morikawa S, Yamamoto T, Nishimura N, et al. Spinal muscular atrophy: from gene discovery to clinical trials. Ann Hum Genet. 2013;77:435–63.PubMedGoogle Scholar
  29. Tomaszewicz K, Kang P, Wu B-L. Detection of homozygous and heterozygous SMN deletions of spinal muscular atrophy in a single assay with multiplex ligation-dependent probe amplification. Beijing Da Xue Xue Bao. 2005;37:55–7.PubMedGoogle Scholar
  30. Scarciolla O, Stuppia L, De Angelis MV, Murru S, Palka C, Giuliani R, et al. Spinal muscular atrophy genotyping by gene dosage using multiple ligation-dependent probe amplification. Neurogenetics. 2006;7:269–76.View ArticlePubMedGoogle Scholar
  31. Bell CJ, Dinwiddie DL, Miller NA, Hateley SL, Ganusova EE, Mudge J, et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med. 2011;3:65ra4.PubMed CentralView ArticlePubMedGoogle Scholar
  32. McVean GA, Altshuler Co-Chair DM, Durbin Co-Chair RM, Abecasis GR, Bentley DR, Chakravarti A, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491:56–65.View ArticlePubMedGoogle Scholar
  33. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26:589–95.PubMed CentralView ArticlePubMedGoogle Scholar
  34. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, del Angel G, Levy-Moonshine A, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013;11:11.10.1–11.10.33.Google Scholar
  35. Peeters K, Chamova T, Jordanova A. Clinical and genetic diversity of SMN1-negative proximal spinal muscular atrophies. Brain. 2014;137:2879–96.PubMed CentralView ArticlePubMedGoogle Scholar
  36. Alías L, Barceló MJ, Bernal S, Martínez-Hernández R, Also-Rallo E, Vázquez C, et al. Improving detection and genetic counseling in carriers of spinal muscular atrophy with two copies of the SMN1 gene. Clin Genet. 2014;85:470–5.View ArticlePubMedGoogle Scholar
  37. Mailman MD, Hemingway T, Darsey RL, Glasure CE, Huang Y, Chadwick RB, et al. Hybrids monosomal for human chromosome 5 reveal the presence of a spinal muscular atrophy (SMA) carrier with two SMN1 copies on one chromosome. Hum Genet. 2001;108:109–15.View ArticlePubMedGoogle Scholar
  38. Smith M, Calabro V, Chong B, Gardiner N, Cowie S, Sart du D. Population screening and cascade testing for carriers of SMA. Eur J Hum Genet. 2007;15:759–66.View ArticlePubMedGoogle Scholar
  39. Luo M, Liu L, Peter I, Zhu J, Scott SA, Zhao G, et al. An Ashkenazi Jewish SMN1 haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy. Genet Med. 2014;16:149–56.View ArticlePubMedGoogle Scholar
  40. Wirth B, Schmidt T, Hahnen E, Rudnik-Schöneborn S, Krawczak M, Müller-Myhsok B, et al. De novo rearrangements found in 2 % of index patients with spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications for genetic counseling. Am J Hum Genet. 1997;61:1102–11.PubMed CentralView ArticlePubMedGoogle Scholar
  41. Rehm HL. Disease-targeted sequencing: a cornerstone in the clinic. Nat Rev Genet. 2013;14:295–300.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Larson et al. 2015